retatrutide ly3437943 parkinson's disease clinical trial TRIUMPH-4: Topline Data Highlights Retatrutide's Significant Weight Loss Effects Trial of Lixisenatide in Early

Basal insulin therapy should be considered when introducing dual or triple therapy and should be intensified adding a mealtime insulin or a GLP-1 RA when glycemic control needs to be optimized [1]

Injectable Wegovy can be used in a wider population, with approval for use in patients 12 years of age and older for weight loss, and an additional indication for metabolic dysfunction-associated steatohepatitis (MASH) in adults

In Phase 2 trials published in the *New England Journal of Medicine* (2023), participants lost an average of 17.5% of body weight at the highest dose over 24 weeks outperforming tirzepatide and semaglutide in head-to-head data comparisons

FPG: fasting plasma glucose

For a head-to-head breakdown, our semaglutide vs tirzepatide comparison page lays out every meaningful difference